Table 1 General characteristics of patients who initiated ART from 2008 to 2015

Total

6530 (100%)

1636 (100%)

182 (100%)

3787 (100%)

430 (100%)

495 (100%)

Sex

 Male

4097 (62.7%)

941 (57.5%)

110 (60.4%)

2453 (64.8%)

284 (66.0%)

309 (62.4%)

 Female

2433 (37.3%)

695 (42.5%)

72 (39.6%)

1334 (35.2%)

146 (34.0%)

186 (37.6%)

Age

 Median years (IQR)

41 (34–49)

44 (37–51)

39 (34–46)

40 (33–48)

41 (34–39)

42 (35–50)

 ≤ 30

940 (14.4%)

131 (8.0%)

29 (15.9%)

665 (17.6%)

56 (13.0%)

59 (11.9%)

 31–40

2174 (33.3%)

474 (29.0%)

70 (38.5%)

1305 (34.5%)

154 (35.8%)

171 (34.5%)

 > 40

3416 (52.3%)

1031 (63.0%)

83 (45.6%)

1817 (48.0%)

220 (51.2%)

265 (53.5%)

Education

 Post-secondary school or more

1400 (21.4%)

229 (14.0%)

25 (13.7%)

1026 (27.1%)

70 (16.3%)

50 (10.1%)

 Secondary school or less

5130 (78.6%)

1407 (86.0%)

157 (86.3%)

2761 (72.9%)

360 (83.7%)

445 (89.9%)

Occupation

 Farmer

3943 (60.4%)

1197 (73.2%)

73 (40.1%)

2049 (54.1%)

259 (60.2%)

365 (73.7%)

 Other

2552 (39.1%)

436 (26.7%)

108 (59.3%)

1709 (45.1%)

171 (39.8%)

128 (25.9%)

Marital status

 Unmarried

1659 (25.4%)

326 (19.9%)

29 (15.9%)

1105 (29.2%)

103 (24.0%)

96 (19.4%)

 Married

4871 (74.6%)

1310 (80.1%)

153 (84.1%)

2682 (70.8%)

327 (76.0%)

399 (80.6%)

Route of HIV infection

 Sexual transmission

2647 (40.5%)

427 (26.1%)

78 (42.9%)

1917 (50.6%)

131 (30.5%)

94 (19.0%)

 Other

3883 (59.5%)

1209 (73.9%)

104 (57.1%)

1870 (49.4%)

299 (69.5%)

401 (81.0%)

Initial ART regimens

 D4T/3TC/EFV or NVP

2953 (45.2%)

600 (20.3%)

87 (2.9%)

1888 (63.9%)

199 (6.7%)

179 (6.1%)

 AZT/3TC/EFV or NVP

1846 (28.3%)

667 (36.1%)

59 (3.2%)

889 (48.2%)

106 (5.7%)

125 (6.8%)

 TDF/3TC/EFV or NVP

555 (8.5%)

45 (8.1%)

1 (0.2%)

454 (81.8%)

39 (7.0%)

16 (2.9%)

 Other regimens

1176 (18.0%)

324 (27.6%)

35 (3.0%)

556 (47.3%)

86 (7.3%)

175 (14.9%)

ART regimens at survey

 D4T/3TC/EFV or NVP

2760 (42.3%)

596 (21.6%)

70 (2.5%)

1795 (65.0%)

161 (5.8%)

138 (5.0%)

 AZT/3TC/EFV or NVP

1321 (20.2%)

269 (20.4%)

59 (4.5%)

825 (62.5%)

75 (5.7%)

93 (7.0%)

 TDF/3TC/EFV or NVP

1014 (15.5%)

149 (14.7%)

17 (1.7%)

762 (75.1%)

51 (5.0%)

35 (3.5%)

 Other first-line regimens

125 (1.9%)

19 (15.2%)

2 (1.6%)

61 (48.8%)

19 (15.2%)

24 (19.2%)

 PI/r-based regimens

1310 (20.1%)

603 (46.0%)

34 (2.6%)

344 (26.3%)

124 (9.5%)

205 (15.6%)

Duration of ART (months)

 Median months (IQR)

33 (17–50)

46 (23–61)

35 (24–50)

27 (15–48)

28 (17–49)

45 (22–57)

 12–24

2576 (39.4%)

444 (27.1%)

45 (24.7%)

1748 (46.2%)

193 (44.9%)

146 (29.5%)

 > 24

3954 (60.6%)

1192 (72.9%)

137 (75.3%)

2039 (53.8%)

237 (55.1%)

349 (70.5%)

CD4 cell counts (cells/μL) at survey

 Median cells/μL (IQR)

340 (234–443)

353 (256–452)

272 (189–351)

362 (260–460)

242 (157–328)

165 (69–264)

 < 200

837 (12.8%)

195 (11.9%)

58 (31.9%)

244 (6.4%)

130 (30.2%)

210 (42.4%)

 ≥ 200

5693 (87.2%)

1441 (88.1%)

124 (68.1%)

3543 (93.6%)

300 (69.8%)

285 (57.6%)

HIV viral load (copies/mL) at survey

 Median log₁₀ copies/mL (IQR)

1.3 (1.3–2.5)

2.2 (2.2–2.5)

1.7 (1.6–2.9)

1.3 (0.9–1.3)

4.3 (3.7–4.8)

4.4 (3.9–5.0)

 < 1000

5605 (85.8%)

1636 (100.0%)

182 (100.0%)

3787 (100.0%)

0 (0.0%)

0 (0.0%)

 ≥ 1000

925 (14.2%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

430 (100.0%)

495 (100.0%)

Missed doses in the past month

 No

4828 (73.9%)

993 (60.7%)

100 (54.9%)

3178 (83.9%)

318 (74.0%)

239 (48.3%)

 Yes

1702 (26.1%)

643 (39.3%)

82 (45.1%)

609 (16.1%)

112 (26.0%)

256 (51.7%)